BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

February 28, 2015

Conditions
GBMGlioblastoma MultiformeGliosarcoma
Interventions
DRUG

PSMA ADC

2.5 mg/kg, IV, over 60 minutes every 3 weeks

Trial Locations (2)

75235

UT Southwestern, Dallas

02903

Rhode Island Hospital, Providence

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

collaborator

Rhode Island Hospital

OTHER

collaborator

University of Texas

OTHER

lead

Heinrich Elinzano, MD

OTHER

NCT01856933 - BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) | Biotech Hunter | Biotech Hunter